Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 11;220(2):e20221333. doi: 10.1084/jem.20221333

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Zhou et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 3. — Systemic cytokine release and myelopoiesis with αCTLA-4 therapy in inflammation-prone conditions. Stat3^Δ/Δ and Stat3^+/+ mice with B16-OVA tumors were treated biweekly for 2 wk with IgG or αCTLA-4. Serum cytokines and spleen and BM immune cells were analyzed 18–19 d after tumor establishment and completion of therapy. (A) Mean concentration of differently expressed cytokines in serum, determined by multiplex assays, fold change absolute log₂ > 1; n = 13–17 per group. (B) Serum cytokines from individual mice analyzed by multiplex assays; n = 13–17 per group. (C) tSNE plot showing prospective clustering of live spleen cells merged from the four experimental groups (left); distribution of spleen immune cells, colored based on experimental groups (right); n = 6–7 in each group. (D) Neutrophil and monocyte amounts in spleen; n = 11–12 per group. (E) Representative flow plots showing CD34⁺ CD16/32⁻ CMPs, CD34⁺ CD16/32⁺ GMPs, and CD34⁻ CD16/32⁻ MEPs (megakaryocyte-erythroid progenitors) gated from the lin⁻ Sca-1⁻ CD117⁺ population. (F) Absolute amounts of HSCs, CMPs, GMPs in each experimental group; n = 9–10 per group. (G) Tumor size over time; n = 24–30 per group. (H) STAT3 expression in tumor-infiltrating DCs (CD11c⁺) or myeloid cells (CD11b⁺ CD11c⁻) determined by immunoblotting. The filter was cut horizontally to separate differentially sized proteins and probed with antibodies to STAT3 or tubulin. The filters were reassembled according to the original gel orientation for each exposure time. (I) tSNE plots showing merged CD45⁺ CD3⁺ cells from the four experimental groups (left), and tSNE plots of aggregated CD45⁺ CD3⁺ cells of individual experimental groups (right); n = 6–8 per group. (J) Number of tumor-infiltrating CD8⁺ T cells, OVA-specific SIINFEKL/H-2Kb pentamer⁺ CD8⁺ T cells, CD4⁺ Foxp3⁻ T_eff cells, CD4⁺ Foxp3⁺ Treg, and CD8⁺/Treg ratios. For SIINFEKL/H-2Kb pentamer⁺ CD8⁺ T cells, n = 6–8 per group; for other plots, n = 18–21 per group. Data shown as mean ± SEM. Results from two to five independent experiments. Data were analyzed by one-way ANOVA (B, D, F, and J) or two-way ANOVA (G). * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Source data are available for this figure: SourceData F3.